Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02395172 · ClinicalTrials.gov registry record · Phase 3
Avelumab in Non-Small Cell Lung Cancer (JAVELIN Lung 200)
A Phase 3 study, sponsored by EMD Serono Research & Development Institute.
- Completed
- Registry status
- Phase 3
- Development phase
- 792
- Enrollment target
NCT02395172 is a Phase 3 study that has completed, run by EMD Serono Research & Development Institute. The registered enrollment target is 792 participants.
The verdict
NCT02395172, a Phase 3 study, has completed, sponsored by EMD Serono Research & Development Institute.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 792 participants
- Enrollment target
Study Summary
The main purpose of this study was to demonstrate superiority with regard to overall survival of avelumab versus docetaxel in participants with programmed death ligand 1 (PD-L1) positive, non-small cell lung cancer (NSCLC) after failure of a platinum-based doublet.
Interventions
- DRUG Docetaxel
- DRUG Avelumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 792 participants |
| Start Date | 2015-03-24 |
| Est. Completion | 2019-12-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02395172
The ClinicalTrials.gov registry entry for NCT02395172 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 792 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is EMD Serono Research & Development Institute, which has 81 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Docetaxel is the first listed.
NCT02395172 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02395172 about?
NCT02395172 is a clinical study titled "Avelumab in Non-Small Cell Lung Cancer (JAVELIN Lung 200)". The main purpose of this study was to demonstrate superiority with regard to overall survival of avelumab versus docetaxel in participants with programmed death ligand 1 (PD-L1) positive, non-small cell lung cancer (NSCLC) after failure of a platinum-based doublet.
What is the current status of trial NCT02395172?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 792 participants. The study started on 2015-03-24. Estimated completion is 2019-12-03.
What interventions are being tested in trial NCT02395172?
The interventions under investigation include: Docetaxel (DRUG), Avelumab (DRUG).
Who is sponsoring clinical trial NCT02395172?
This trial is sponsored by EMD Serono Research & Development Institute, which has 81 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.